Tretinoin
- Generic Name
- Tretinoin
- Brand Names
- Altreno, Atralin, Biacna, Refissa, Renova, Retin-A, Stieva-A, Tri-luma, Twyneo, Veltin, Vesanoid, Ziana
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28O2
- CAS Number
- 302-79-4
- Unique Ingredient Identifier
- 5688UTC01R
- Background
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, ...
- Indication
Oral tretinoin is indicated for induction of remission in adults and pediatric patients one year of age and older with acute promyelocytic leukemia (APL), characterized by the presence of t(15;17) translocation or presence of PML/RARα gene expression and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-base...
- Associated Conditions
- Acne Vulgaris, Alopecia, Cornification and dystrophic skin disorders, FAB classification M3 Acute promyelocytic leukemia, Fine Wrinkles, Photodamaged Skin, Skin hyperpigmentation, Keratinization disorders of the feet, Keratinization disorders of the hand, Moderate Melasma, Mottled hyperpigmentation, Severe Melasma, Severe, recalcitrant Cystic acne, Tactile roughness of facial skin
- Associated Therapies
- -
ATRA, Celecoxib, and Itraconazole as Maintenance
- Conditions
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 1
- Registration Number
- NCT02401295
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2015-01-15
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 158
- Registration Number
- NCT02339740
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸Naval Medical Center -San Diego, San Diego, California, United States
Study of TCP-ATRA for Adult Patients With AML and MDS
- Conditions
- Interventions
- First Posted Date
- 2014-10-23
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 17
- Registration Number
- NCT02273102
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible
- First Posted Date
- 2014-10-10
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- Martin-Luther-Universität Halle-Wittenberg
- Target Recruit Count
- 16
- Registration Number
- NCT02261779
- Locations
- 🇩🇪
Universitaetsklinikum Halle, Halle, Germany
Bioequivalence Study of Tretinoin Gel 0.05% to Brand Tretinoin Gel
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Spear Pharmaceuticals
- Target Recruit Count
- 574
- Registration Number
- NCT02249767
A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- South China Children's Leukemia Group
- Target Recruit Count
- 176
- Registration Number
- NCT02200978
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2014-06-30
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 41
- Registration Number
- NCT02177812
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
Clinical Guidelines for APL Treatment
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 200
- Registration Number
- NCT02020161
- Locations
- 🇪🇸
Hospital La Fe, Valencia, Spain
Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Interventions
- First Posted Date
- 2013-03-29
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Paolo Caimi, MD
- Target Recruit Count
- 12
- Registration Number
- NCT01820624
- Locations
- 🇺🇸
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2017-09-07
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 130
- Registration Number
- NCT01667263
- Locations
- 🇨🇳
Beijing Hospital, Ministry of Health, Beijing, Beijing, China
🇨🇳Beijing Tongren Hospital, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Peking University Insititute of Hematology, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.